Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.38 |
| ▸ | PPARA | Q07869 | 7/20 | 0.38 |
| ▸ | PPARD | Q03181 | 6/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27950301 | 0.90 | PPARG (0.37) | PPARGPPARAPPARDRORCMAOA | |
| SCHEMBL27936024 | 0.88 | PPARG (0.39) | PPARGPPARAPPARDRORCMEN1 | |
| SCHEMBL28807352 | 0.88 | PPARG (0.43) | PPARGPPARAPPARDRORCMAOB | |
| SCHEMBL27950252 | 0.88 | PPARG (0.38) | PPARGPPARAPPARDNR1H4RORC | |
| SCHEMBL27867734 | 0.86 | CCR2 (0.39) | PPARGPPARAPPARDCCR2NR1H4 | |
| SCHEMBL27950300 | 0.85 | PPARG (0.40) | PPARGPPARAPPARDCCR2NR1H4 | |
| SCHEMBL27950238 | 0.85 | POLB (0.44) | PPARGPPARAPPARDRORCKMT2A | |
| Piperazine SCHEMBL27950239 | 0.84 | PPARG (0.36) | PPARGPPARAPPARDRORCMEN1 | |
| SCHEMBL28809330 | 0.84 | PPARG (0.37) | PPARGPPARAPPARDRORCMAOA | |
| SCHEMBL27936050 | 0.84 | PPARG (0.37) | PPARGPPARAPPARDRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103554006-A | Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease | FOURNIER LAB SA | 2014-02-05 | — | — | CN | disclosed |